Events targeted at promoting opportunities in alternative protein investment via specialized funds could facilitate and diversify investment.
More frameworks for academic-industry collaboration could help build talent pipelines, create research commercialization pathways, and drive alignment on research priorities.
More alternative protein capacity—different geographies, expertise, and programming—is needed in the incubator and accelerator landscape to de-risk venture capital investment.
Corporations can build out venture capital arms—including building dedicated incubators and opening their facilities—to facilitate strategic partnerships.
In strain development, many of the selectable markers confer traits like antibiotic or herbicide resistance. While some auxotrophic selection markers exist, these are often not orthogonal and thus not amenable to stacking for multi-trait selection.
Directories of contract manufacturers for plant-based production, fermentation, and animal cell culture
The alt protein industry would benefit from better open-access directories of co-manufacturers interested in producing alternative proteins, including more detail on their equipment and capabilities.
Investment platforms are needed for deal flow and coordinating hand-offs from pre-seed (angels and accelerators), seed/early-stage, and growth/later-stage investors and acquirers.
Dedicated brokers, consultants, directories, and other matching mechanisms could help connect alternative protein companies to engineering/design/construction firms with relevant experience and interest in the alternative protein sector.
An alternative protein data lake could contain anonymized data from processing runs across many manufacturers, informing processing improvements and aiding process failure troubleshooting.